# OnCo record paper-nct04547166-med-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct04547166-med-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct04547166-med-2024" ;
  schema:name "First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial"@en ;
  schema:description "Published report from the trial registered as NCT04547166, in Med (New York, N.Y.) (2024), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct04547166-med-2024/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.medj.2024.05.009>, <https://pubmed.ncbi.nlm.nih.gov/38870931/>, <https://europepmc.org/article/MED/38870931>, <https://clinicaltrials.gov/study/NCT04547166> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/j.medj.2024.05.009> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Wang ZX, Peng J, Liang X, et al." ;
  onco:trials <https://onco.cc/trials/nct04547166/> .